State of the art - sirtuin 1 in kidney pathology - clinical relevance.
Kidney
Kidney pathology
SIRT1
Sirtuin
Journal
Advances in medical sciences
ISSN: 1898-4002
Titre abrégé: Adv Med Sci
Pays: Netherlands
ID NLM: 101276222
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
24
07
2018
revised:
17
11
2018
accepted:
19
04
2019
pubmed:
28
5
2019
medline:
14
4
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
Sirtuins represent a group of nicotinamide adenine dinucleotide dependent histone deacetylases, which regulates various biological pathways by promoting chromatin silencing and transcriptional repression. Therefore, they are linked to cellular energy metabolism, mitochondrial biogenesis, stress response, apoptosis, inflammation and fibrosis. Since sirtuin 1 became a promising candidate for targeted therapies of numerous conditions, researchers have been investigating its activator. As for now, natural agents and antidiabetic drug - metformin, have been found to activate sirtuin 1. Sirtuin 1 is able to improve kidney outcomes by direct impact on kidney cells, regulation of non-specific processes generally involved in pathogenesis of age-dependent and metabolic disorders and improvement of the comorbid diseases. This review discusses the state of the art knowledge on the role of sirtuin 1 on kidney pathology.
Identifiants
pubmed: 31125865
pii: S1896-1126(18)30226-8
doi: 10.1016/j.advms.2019.04.005
pii:
doi:
Substances chimiques
NAD
0U46U6E8UK
Sirtuin 1
EC 3.5.1.-
Sirtuins
EC 3.5.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-364Informations de copyright
Copyright © 2019 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.